Pulmonary Arterial Hypertension Global Market Report 2023 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE 5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2023-2032

Respiratory devices and equipment (diagnostic) are used in the diagnosis of respiratory disorders such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. The main products of the respiratory devices and equipment (diagnostic) market are instruments and devices, assays, and reagents. The respiratory instruments and devices are used to diagnose respiratory disorders. The test type included is traditional diagnostic tests, mechanical tests, imaging tests, and molecular diagnostic tests that are used to diagnose chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis, and other diseases. These are used in hospital/clinical laboratories, physician offices, reference laboratories, and other end users. The global respiratory devices and equipment (diagnostic) market is segmented - 1)By Product: Instruments And Devices, Assays And Reagents 2) By Test Type: Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests 3)By Disease Type: Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases 4) By End User: Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users The global respiratory devices and equipment (diagnostic) market size grew from $6.93 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global respiratory devices and equipment (diagnostic) is expected to grow from $10.22 billion in 2027 at a CAGR of 8.0%. The increasing prevalence of various respiratory diseases contributed to the global respiratory devices and equipment market growth by increasing the use of diagnostic devices and equipment for diagnosis and treatment. Diseases such as chronic obstructive pulmonary disease (COPD) are more prevalent in the geriatric population. COPD is a type of obstructive lung disease that results in long-term breathing problems. For instance, in June 2021, according to the world health organization data, chronic obstructive pulmonary disease (COPD) is the third disease on the list of causing death in the world. There are about 3.23 million deaths that are caused by chronic obstructive pulmonary disease (COPD).. Thus, the increased number of such cases has surged the demand for diagnostic devices and equipment, therefore driving the growth of respiratory devices and equipment (diagnostic) market. Major players in the respiratory devices and equipment (diagnostic) market are ResMed. Inc., Medtronic PLC., Massimo Corporation, Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V, Smiths Medical, GE Healthcare, Chart Industries, Philips Healthcare, and Becton Dickinson and Company. Stringent regulatory practices are expected to negatively impact the growth of diagnostic respiratory devices in the forecast period. In the USA, respiratory devices undergo a strict approval process as they come under Class III devices (that pose a significant risk to patients) as per the Food and Drug Administration (FDA) classification of medical devices. These devices require clinical evidence that supports their intended use unlike, Class I and II devices, to receive marketing approval. In countries such as China, the approval process for medical devices, especially for devices used for support or sustenance, is strict and time-consuming. Such a process has slowed the entry of medical devices into the market, thus restraining the growth. Companies in the market are increasingly investing in portable and wireless diagnostic respiratory devices. The trend is being driven by the ease of handling, cost-effectiveness, advanced features of these devices, and their suitability for use at home care organizations. Innovative technology-enabled portable respiratory devices are being launched into the market, which, unlike traditional devices, can be used for immediate diagnosis of vital signs, for example, the patients’ respiratory rate and the pulse rate. For instance, in July 2021, Tidal Medical Technologies received U.S FDA approval for the use of its InSee incentive spirometer accessory for detection of medical condition and symptoms of COVID-19 in hospital settings. In June 2020, AireHealth acquired BreathResearch for an undisclosed amount. The deal comprises the acquisition of IP, research, and patents, which include work on machine learning analytics for respiratory condition tracking. BreathResearch is a US-based company engaged in converting the airwaves of breathing into sound waves producing new respiratory analytics which improve health, fitness, and performance. Asia-Pacific was the largest region in the respiratory devices and equipment (diagnostic) market in 2022. North America was the second largest region in the global respiratory devices and equipment (diagnostic) market share. Eastern Europe was the smallest region in the global respiratory devices and equipment (diagnostic) market. The regions covered in the global respiratory devices and equipment (diagnostic) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (diagnostic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory devices and equipment (diagnostic) market consist of sales of spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers that are used for diagnosis of respiratory diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The respiratory devices and equipment (diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (diagnostic) market statistics, including respiratory devices and equipment (diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (diagnostic) market share, detailed respiratory devices and equipment (diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (diagnostic) industry. This respiratory devices and equipment (diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-hypertensive drugs refer to a group of medications used to treat high blood pressure (high blood pressure). The goal of antihypertensive therapy is to prevent the negative effects of high blood pressure, such as myocardial infarction and stroke. The main therapeutics of anti-hypertensive drugs are diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, also known as water pills, are medications that increase the amount of water and salt excreted by the body in the form of urine. The various sources of diseases include primary hypertension and secondary hypertension, which are treated in hospitals, clinics, and at home care. The global anti-hypertensive drugs market is segmented - 1) By Therapeutics: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators 2) By Disease Source: Primary Hypertension, Secondary Hypertension 3) By End Users: Hospitals, Clinics, Homecare The global anti-hypertensive drugs market size will grow from $37.65 billion in 2022 to $38.70 billion in 2023 at a compound annual growth rate (CAGR) of 2.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The anti-hypertensive drugs market size is expected to grow to $41.19 billion in 2027 at a CAGR of 1.6%. A sedentary lifestyle is a major driver of the growth of the anti-hypertensive drug market. Consumption of junk food, lack of proper healthy and balanced diet, and lack of proper sleep due to irregular work shifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed with hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. Furthermore, in June 2021, according to the World Health Organization data 2021, a Switzerland-based Government agency responsible for international public health, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market. Major players in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca PLC., Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer Inc., Novartis AG, Sanofi SA, United Therapeutics, Ranbaxy Laboratories, Bayer AG, Lupin Limited, Boehringer Engelheim GmbH, Sun Pharmaceuticals LLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Roche, Abbott, Gilead, Actelion, and Teva Pharmaceutical Industries Ltd. Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the anti-hypertensive drugs market. Firstly, most people in developing nations neglect their health checkups and are not aware of their existing hypertension condition in them until they detect extreme symptoms. Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market. For example, BMC Research notes published a research survey (from a developing country) which states that out of the total 112 hypertensive subjects with stroke, only 17% of them were adherent to antihypertensive medications. Lack of awareness and low drug adherence restraint the growth of the antihypertensive market. Of late, there has been a rise in the use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When the two drugs are combined with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well. The US Food and Drug Administration (FDA) issued guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. The US FDA expects to see a reduction in adverse effects for combinations that include doses below each drug’s maximum dose compared to single drug regimens at their maximum dose. Earlier physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their program, current guidelines recommend starting patients on two drugs at less than their full doses. Hence, this guidance would keep a check on fixed-combination drugs. North America was the largest region in the anti-hypertensive drugs market in 2022. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the global anti-hypertensive drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anti-hypertensive drugs market research report is one of a series of new reports from The Business Research Company that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticoagulants refer to a drug used to prevent and treat blood clots in the heart and blood arteries. called a blood thinner as well. It is utilised to slow down the body's clotting process. These are blood thinners, but they do not thin the blood, instead, they avoid or minimize clots or thrombi. The main drug classes of anticoagulants are Factor Xa Inhibitor, Heparin & LMWH, Vitamin K Antagonist, and others. Factor Xa inhibitors are anticoagulants that inhibit clot formation by specifically and reversibly blocking the function of clotting factor Xa. The different routes of administration include oral anticoagulants, and injectable anticoagulants and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacy. It is used in venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, and others and is used in hospitals, home care, speciality centres, and others. The global anticoagulants market is segmented - 1) By Drug Class: Factor Xa Inhibitor, Heparin And LMWH, Vitamin K Antagonist, Other Drug Classes 2) By Route Of Administration: Oral Anticoagulant, Injectable Anticoagulant 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By Application: Venous Thromboembolism, Atrial Fibrillation Or Flutter, Coronary Artery Disease, Other Applications 5) By End User: Hospitals, Homecare, Specialty Centers, Other End-Users The global anticoagulants market size will grow from $40.63 billion in 2022 to $44.81 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the anticoagulants is expected to grow to $66.32 billion in 2027 at a CAGR of 10.3%. The increasing cardiovascular diseases are a key factor driving the growth of the anticoagulants market over the coming years. CVDs (cardiovascular diseases) are a category of heart and blood vessel problems. Cardiovascular diseases (CVDs) are the primary, source of death worldwide with low- and middle-income nations accounting for three-quarters of CVD deaths. Anticoagulation pharmacotherapy known as direct oral anticoagulants is used to minimize thrombosis in a variety of cardiovascular situations. According to the World Health Organization report in 2021, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85% of these deaths. Therefore, the increasing cardiovascular diseases drive the growth of the anticoagulants market. Major players in the anticoagulants market are GlaxoSmithKline plc., Pfizer Inc., Sanofi, Mylan, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo, Alexion Pharmaceuticals Inc., Otsuka, Leo Pharma, Eisai Co. Ltd., and Amphastar Pharmaceutica. The ongoing clinical trials of anticoagulant treatments for COVID-19 are shaping the anticoagulants market. Major companies operating in the anticoagulants sector are concentrating on establishing clinical trials of anticoagulant medications to lower the risk of COVID-19-related blood clotting in adults. For instance, in March 2021, The National Institutes of Health (NIH) in the USA started the final of three Phase III clinical trials of blood thinners (anticoagulants) to prohibit life-threatening blood clots in elderly people with COVID-19. The ACTIV-4 trials will help to resolve concerns about the use of anticoagulants also known as antithrombotics in the treatment of COVID-19. In July 2020, Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company acquired Portola Pharmaceuticals Inc., for an amount of $1.41 billion. Through this acquisition Andexxa, a factor Xa inhibitor reversal agent marketed as Ondexxya in Europe has been added to Alexion Pharmaceuticals Inc.,'s commercial portfolio. Portola Pharmaceuticals Inc., is a US-based clinical-stage biopharmaceutical company with an anticoagulant Bevyxxa under its portfolio. North America was the largest region in the anticoagulants market in 2022. The regions covered in the anticoagulants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the anticoagulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anticoagulants market research report is one of a series of new reports from The Business Research Company that provides anticoagulants market statistics, including anticoagulants industry global market size, regional shares, competitors with an anticoagulants market share, detailed anticoagulants market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. This anticoagulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiovascular medical lasers are used in the treatment of medical conditions related to the heart. These lasers are commonly used during transmyocardial laser revascularization. The cardiovascular medical lasers market covered in this report is segmented by type into excimer lasers and carbon dioxide laser. The carbon dioxide laser aids in the removal of thin layers of skin while causing minimal damage to surrounding structures.These are used in various applications such as laser vascular anastomosis, transmyocardial laser revascularization, and laser angioplasty for peripheral arterial diseases that are used by end users such as hospitals, specialty clinics, and ambulatory surgery centres. The global cardiovascular medical lasers market is segmented - 1) By Type: Excimer Laser, Carbon Dioxide Laser 2) By Application: Laser Vascular Anastomosis, Transmyocardial Laser Revascularization, and Laser Angioplasty for Peripheral Arterial Diseases 3) By End Use: Hospitals, Specialty Clinics, Ambulatory Surgery Centers The global cardiovascular medical lasers market size grew from $0.15 billion in 2022 to $0.21 billion in 2023 at a compound annual growth rate (CAGR) of 46.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cardiovascular medical lasers is expected to grow from $0.9 billion in 2027 at a CAGR of 43.2%. The rising prevalence of cardiovascular diseases is expected to drive the cardiovascular medical laser market. The increased prevalence of cardiovascular diseases can be attributed to the increase in the use of smoking, physical inactivity, and an unhealthy diet. For instance, according to the Centers for Disease control and prevention (CDC), 697,000 people died from heart diseases in 2020. According to the British Heart Foundation, coronary heart disease is responsible for around 64,000 deaths in the UK each year, an average of 180 people each day, or one death around every eight minutes. One in seven men and one in 12 women in the UK die from coronary heart disease. Therefore, the increasing prevalence of cardiovascular diseases is expected to drive the growth of cardiovascular medical lasers market. Major players in the cardiovascular medical lasers market are Boston Scientific Corp., Cardiovascular Systems, AngioDynamics, Royal Philips NV, and RA Medical Systems. Alternative treatment methods for cardiovascular ailments are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the cardiovascular medical laser market. Treatments of heart diseases using medical procedures such as coronary angioplasty, stent implantation, thrombolytic therapy, coronary artery bypass graft surgery (CABG), artificial pacemaker surgery, defibrillation, and heart valve surgery are more commonly used for the treatment of heart disease compared to the treatments employing lasers. According iData Research, around 340,000 CABG procedures are performed per year in the United States. This trend is expected to continue during the forecast period and limit the demand for cardiovascular medical lasers. Cardiovascular medical laser manufacturers are constantly investing in technologies for faster diagnosis and efficient treatment of heart conditions. Areas of technological advances include new wavelengths, more rugged setups, lower-cost systems, and other advancements are being combined with minimally invasive techniques. FDA cleared Ra Medical’s vascular products including cardiovascular lasers that can be used to treat peripheral arteries and veins. The laser works at 308-nanometer wavelength, which breaks chemical bonds and decomposes the blockage into its part, thereby reducing the risk for the patient. In October 2021, Laser MD Medspa, a US-based medical spa services company, acquired Young Medical Spa for an undisclosed amount. The acquisition would expand the company’s footprint in the state of Pennsylvania by adding four locations. Young Medical is a US-based provider of a full suite of cosmetic and aesthetic treatments, including laser hair removal, botox treatment, and others. North America was the largest region in the cardiovascular medical lasers market in 2022. Asia-Pacific was the second largest region in the global cardiovascular medical lasers market report. The regions covered in the global cardiovascular medical lasers market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiovascular medical lasers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cardiovascular medical lasers market consists of sales of instruments such as excimer lasers and carbon dioxide lasers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The cardiovascular medical lasers market research report is one of a series of new reports from The Business Research Company that provides cardiovascular medical lasers market statistics, including cardiovascular medical lasers industry global market size, regional shares, competitors with a cardiovascular medical lasers market share, detailed cardiovascular medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular medical lasers industry. The cardiovascular medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioabsorbable stents are tubes inserted into blood vessels to unblock passageways and dissolve in the body after a period of time. The main products of bioabsorbable stents are polymer-based bioabsorbable stents and metal-based bioabsorbable stents. Bioresorbable stents (BRS) or vascular scaffolds are coronary stents that can fully dissolve in the body. It is also segmented by absorption rate into slow-absorption stents and fast-absorption that are used in various applications such as coronary artery diseases, and peripheral artery diseases. The global bioabsorbable stents market is segmented - 1) By Product Type: Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents 2) By Absorption Rate: Slow- absorption stents, Fast- absorption Stents 3) By Applications: Coronary Artery Diseases, Peripheral Artery Diseases The global bioabsorbable stents market size grew from $0.31 billion in 2022 to $0.34 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of bioabsorbable stents is expected to grow from $0.49 billion in 2027 at a CAGR of 9.2%. Increasing cardiovascular diseases is a key factor driving the growth of the bioabsorbable stents market. Cardiovascular disorders are the leading cause of death across the world and 4 out of 5 cardiovascular deaths are caused by strokes and heart attacks. Moreover, one-third of such deaths occur prematurely in people under the age of 70. Bioresorbable stents are built primarily to reduce these risks of late complications, such as scaffold thrombosis or restenosis, that can happen when a conventional metal stent's rigid metal backbone remains permanently rooted in the diseased vessel. According to the American Heart Association, it is estimated that more than 23.6 million die due to cardiovascular diseases by 2030. Therefore, increasing cardiovascular diseases are expected to drive the bioabsorbable stents industry. Major players in the bioabsorbable stents market are Abbott Laboratories, Reva Medical, Elixir Medical Corporation, Biotronik SE & Co. KG, Amaranth Medical Inc., Zorion Medical, Tepha, Inc., S3V Vascular Technologies, ICON Interventional Systems, and Arterius Limited. The risks associated with bioabsorbable stents restrain the growth of the market. The high risks with stents force companies to withdraw their devices from the market reducing the revenues from bioabsorbable stents. For instance, Abbott had to withdraw its product Absorb and Boston Scientific terminated their Renuvia scaffold development program as the devices showed a high risk of myocardial infarction and thrombosis. This was due to the non-uniform structure of the polymer used in the stents that makes the device susceptible to large deformation and causes flow disruption. The drug-eluting stent (DES) is gaining significant popularity in the bioabsorbable stents market. The drug-eluting stent (DES) device was designed to avoid the regeneration of tissue that would otherwise obstruct the artery and this was a new step forward in the treatment of peripheral artery disease. Boston Scientific launched its self-expanding drug-eluting stent (DES) peripheral artery disease (PAD) scheme which helped the company to expand its PAD portfolio. North America was the largest region in the bioabsorbable stents market in 2022. Western Europe was the second largest region in the bioabsorbable stents market report. The regions covered in the bioabsorbable stents industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the bioabsorbable stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The bioabsorbable stents market consists of sales of polymer-based bioabsorbable stents and metal-based bioabsorbable stents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bioabsorbable stents market research report is one of a series of new reports from The Business Research Company that provides bioabsorbable stents market statistics, including bioabsorbable stents industry global market size, regional shares, competitors with a bioabsorbable stents market share, detailed bioabsorbable stents market segments, market trends and opportunities, and any further data you may need to thrive in the bioabsorbable stents industry. This bioabsorbable stents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood transfusion diagnostics are used to conduct tests before the transfusion of blood from donor-recipient such as blood grouping disease screening. The main types of blood transfusion diagnostics are instruments and kits, reagents, and others. The blood transfusion diagnostic kits are used to collect and transfuse blood. The technologies involved in blood transfusion diagnostics are western blot, ELISA, nucleic acid amplification, fluorescence assay, and rapid test that are used for various applications such as blood grouping and disease screening. The end-users involved are hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The global blood transfusion diagnostics market is segmented - 1) By Type: Instruments and Kits, Reagents, Other Types 2) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies 3) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test 4) By Application: Blood Grouping, Disease Screening The blood transfusion diagnostics market size grew from $3.65 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of blood transfusion diagnostics is expected to grow from $5.68 billion in 2027 at a CAGR of 9.3%. Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient and will otherwise increase the incidence of infectious disease. According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc., Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., and Beckman Coulter Inc. Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood, and low supply for the high demand of blood. Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions. For example, according to research conducted by India Spend, around 1.18 million units of blood were wasted during storage in the form of discoloration, bacterial contamination, and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market. The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce the turnaround time of the results. NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria that acts as a pathogen in blood, tissue, or urine. NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic's Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic's NAAT technology for their future molecular diagnostic portfolio. The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and the Medicines and Healthcare products Agency (MHRA). For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of the Code of Federal Regulations (CFR). Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. North America was the largest region in the blood transfusion diagnostics market in 2022. Western Europe was the second largest region in the blood transfusion diagnostics industry. The regions covered in the blood transfusion diagnostics analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood transfusion diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood transfusion diagnostics market consists of revenues earned by entities by providing installation and maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood transfusion diagnostics market also includes sales of blood transfusion diagnostics devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The blood transfusion diagnostics market research report is one of a series of new reports from The Business Research Company that provides blood transfusion diagnostics market statistics, including blood transfusion diagnostics industry global market size, regional shares, competitors with a blood transfusion diagnostics market share, detailed blood transfusion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the blood transfusion diagnostics industry. This blood transfusion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood culture tests refer to blood tests used to detect and identify disease-causing microorganisms in the bloodstream. A blood culture test checks for infections caused by microorganisms like bacteria, yeast, and other foreign invaders in a blood sample. The main method of blood culture tests are conventional/manual methods and automated methods. The conventional or manual method of blood culture test is used for detection of invaders like bacteria, yeast, and other microorganisms from a blood specimen. Manual testing is performed by testers who use and test the result in a manual maaner. The blood culture product are consumables, instruments and software and services that uses technology such as culture-based technology, molecular technologies, microarrays, PCR (polymerase chain reaction); PNA-FISH (peptide nucleic acid – fluroscent in situ hybridization) and proteomics technology that are applied in bacteremia, fungemia and mycobacterial detection, used by hospital laboratories, reference laboratories, academic research laboratories, and other laboratories. The global blood culture tests market is segmented - 1) By Method: Conventional/Manual Methods, Automated Methods 2) By Product: Consumables, Instruments, Software and Services 3) By Technology: Culture-Based Technology, Molecular Technologies, Microarrays, PCR (Polymerase Chain Reaction), PNA-FiSH (Peptide Nucleic Acid – Fluroscent in Situ Hybridization), Proteomics Technology 4) By Application: Bacteremia, Fungemia, Mycobacterial Detection 5) By End User: Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, Other Laboratories The global blood culture tests market size grew from $5.51 billion in 2022 to $6.24 billion in 2023 at a compound annual growth rate (CAGR) of 13.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the blood culture tests is expected to grow to $9.31 billion in 2027 at a CAGR of 10.5%. The increase in incidence of infectious diseases is expected to propel the growth of the blood culture test market. Infectious diseases are illnesses caused by pathogens, including viruses, bacteria, fungi, and parasites. These diseases have dangerous microorganisms or pathogens that enter an individual's body from the outside or from an infected person. These infectious diseases, such as COVID-19, tuberculosis, flu, measles, HIV, strep throat, and so on, have the potential to cause momentary pain, significant tissue damage, or even death. The World Health Organization ranks infectious diseases as the second biggest cause of death globally. These increases in the incidence of infectious diseases have led to an increase in the demand for blood culture tests to assist in determining whether a patient has bacteremia/septicemia, a potentially fatal condition, or not. For instance, in 2022, the World Health Organization, stated that approximately 6.4 million people died from COVID-19. Furthermore, due to tuberculosis (TB), a total of 1.5 million people died in 2020 worldwide. Therefore, the increasing incidence of infectious diseases is driving the growth of the blood culture test market. Major players in the blood culture tests market are Becton, Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific Inc., Luminex Corporation, Danaher Corporation, Bruker Corporation, Roche Diagnostics, T2 Biosystems Inc., OpGen Inc., F. Hoffmann-La Roche AG, HiMedia Laboratories Pvt. Ltd., Axiom Laboratories, Abbott Laboratories, Ibis Biosciences Inc., and Magnolia Medical Technologies. The technological innovation is a key trend gaining popularity in the blood culture tests market. Innovation and globalization are creating new prospects for the pharmaceutical, biologics, nutraceuticals, and medical device industries. The desire to bring new products to market safely, quickly, and affordably necessitates producers and manufacturers to build world-class blood culture testing to demonstrate compliance with ever-expanding requirements. These technological innovations reduce costs through accurate and independent safety and performance assurance. For instance, In May 2022, Labcorp, a US-based testing laboratories company, launched Labcorp OnDemandTM at-home collection kit that measures hemoglobin A1c (HbA1c) from a small blood sample. This OnDemand Diabetes test kit employs dried blood technology to provide an overview of the body's average blood sugar levels over time. Through this kit, users can monitor their health status regularly from the comfort of their homes with a prick of the finger and a few drops of blood. In October 2021, Dr. Lal Path Labs, an India-based diagnostic and related healthcare tests provider, acquired Suburban Diagnostics for an 1150 cr ($14.39 million). This acquisition gives LPL access to 44 laboratories and diagnostics centers (one of which is CAP-accredited and five are NABL accredited) and 150+ collection centers. Suburban Diagnostics is an India-based diagnostics center and pathology lab. North America was the largest region in the blood culture tests market in 2022. The regions covered in the blood culture tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood culture tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The blood culture tests include revenues earned by entities by micro sampling technology and blood chemistry analyzer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The blood culture tests market research report is one of a series of new reports from The Business Research Company that provides blood culture tests market statistics, including blood culture tests industry global market size, regional shares, competitors with a blood culture tests market share, detailed blood culture tests market segments, market trends and opportunities, and any further data you may need to thrive in the blood culture tests industry. This blood culture tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood collection devices are devices used to collect blood samples from the body. Blood collection devices are used for health and wellness testing, population studies, or research and preclinical drug studies. The main types of blood collection devices include blood collection tubes, lancets, micro container tubes, and warming devices. The blood collection tubes refer to tubes used for coagulation investigations and sodium citrate-containing blood collection. Blood collection tubes are used for various components and conduct blood into and out of a patient’s body to get tested in the laboratory. Different tests and biochemical assays require various types of sample collection tubes. The different materials used in the manufacturing of blood collection devices include glass, stainless steel, and plastic. They are used in manual and automatic blood collection by hospitals, blood collection centers, diagnostic centers, and others. The global blood collection devices market is segmented - 1) By Type: Blood Collection Tubes, Lancet, Micro Container Tubes, Warming Devices 2) By Method: Manual Blood Collection, Automatic Blood Collection 3) By Material: Glass, Stainless Steel, Plastic 4) By End User: Hospitals, Blood Donation Centers, Diagnostic Center, Other End Users The global blood collection devices market size grew from $6.92 billion in 2022 to $7.39 billion in 2023 at a compound annual growth rate (CAGR) of 6.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the blood collection devices is expected to grow to $9.59 billion in 2027 at a CAGR of 6.8%. The increase in incidence of infectious diseases is driving the growth of the blood collection devices market. Infectious diseases are infections caused by bacteria, viruses, fungi, or parasites. Infectious disorders such as hepatitis B (HBV), hepatitis C (HCV), the human immunodeficiency virus (HIV), malaria, syphilis, and brucellosis are tested through blood collection and sampling. The constant increase in incidences of infectious diseases and its diagnostics activities are expected to boost the utilization of blood collection devices. According to World Health Organization (WHO), in 2021, an estimated 10.6 million people are infected with tuberculosis globally, 1.6 million died, and 1.5 million people acquired HIV in 2021 while 650,000 people lost lives due to it. Therefore, the increase in incidences of infectious diseases is expected to boost demand for blood collection devices during the forecast period. Major players in the blood collection devices market are Becton, Dickinson and Company, Greiner Group, Kabe Labortechnik GmbH, Sarstedt AG & Company, ICU Medical Inc., Grifols SA, Retractable Technologies Inc., Nipro Corporation, Terumo Corporation, Fresenius Kabi AG, Medtronic, and Radiometer Medical ApS. Technology advancement is a key trend gaining popularity in the blood collection devices market. Many companies operating in the blood collection devices market are developing new products or new technologies to meet fast-growing industry demand and enhance their business presence across the globe. The technologically advanced products developed by companies are focused on enhancing comfort and providing advanced protection to customers. For instance, in April 2022, Owen Mumford, a medical device design and manufacturing company, introduced a new venous blood collection portfolio under its Unistik brand. The new portfolio draws on the company's expertise and history in capillary blood sampling to provide a range of venous devices that ensure patient safety, comfort, and quality. The Unistik ShieldLock Ultra combines a one-handed and in-vein activated safety system to reduce the risk of NSIs. The device also has a unique safety feature that, when activated, closes the tube between the needle and the Luer to avoid blood exposure after the needle is removed from the vein. In July 2021, a leading global medical technology company Becton, Dickinson and Company (BD) acquired Velano Vascular for an undisclosed amount. With this acquisition, BD enables health care providers to help eliminate multiple needlesticks for blood sample collection, reducing the pain and discomfort from the process while delivering quality outcomes and increasing patient satisfaction. Velano Vascular is a US-based medical equipment manufacturer committed to enhancing both inpatient blood collection and vascular access. North America was the largest region in the blood collection devices market in 2022. The Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood collection devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood collection devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood collection devices market consists of sales of blood collection tubes, needles and syringes, blood bags, blood collection systems, and lancets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The blood collection devices market research report is one of a series of new reports from The Business Research Company that provides blood collection devices market statistics, including blood collection devices industry global market size, regional shares, competitors with a blood collection devices market share, detailed blood collection devices market segments, market trends and opportunities, and any further data you may need to thrive in the blood collection devices industry. This blood collection devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.